Ontology highlight
ABSTRACT: Background
It is important to select appropriate targeted therapies for subgroups of patients with lung adenocarcinoma who have specific gene alterations.Methods
This prospective study was a multicenter project conducted in Taiwan for assessment of lung adenocarcinoma genetic tests. Five oncogenic drivers, including EGFR, KRAS, BRAF, HER2 and EML4-ALK fusion mutations, were tested. EGFR, KRAS, BRAF and HER2 mutations were assessed by MALDI-TOF MS (Cohort 1). EML4-ALK translocation was tested by Ventana method in EGFR-wild type patients (Cohort 2).Results
From August 2011 to November 2013, a total of 1772 patients with lung adenocarcinoma were enrolled. In Cohort 1 analysis, EGFR, KRAS, HER2 and BRAF mutations were identified in 987 (55.7%), 93 (5.2%), 36 (2.0%) and 12 (0.7%) patients, respectively. Most of these mutations were mutually exclusive, except for co-mutations in seven patients (3 with EGFR + KRAS, 3 with EGFR + HER2 and 1 with KRAS + BRAF). In Cohort 2 analysis, 29 of 295 EGFR-wild type patients (9.8%) were positive for EML4-ALK translocation. EGFR mutations were more common in female patients and non-smokers and KRAS mutations were more common in male patients and smokers. Gender and smoking status were not correlated significantly with HER2, BRAF and EML4-ALK mutations. EML4-ALK translocation was more common in patients with younger age.Conclusion
This was the first study in Taiwan to explore the incidence of five oncogenic drivers in patients with lung adenocarcinoma and the results could be valuable for physicians in consideration of targeted therapy and inclusion of clinical trials.
SUBMITTER: Hsu KH
PROVIDER: S-EPMC4366385 | biostudies-literature | 2015
REPOSITORIES: biostudies-literature
Hsu Kuo-Hsuan KH Ho Chao-Chi CC Hsia Te-Chun TC Tseng Jeng-Sen JS Su Kang-Yi KY Wu Ming-Fang MF Chiu Kuo-Liang KL Yang Tsung-Ying TY Chen Kun-Chieh KC Ooi Hean H Wu Tzu-Chin TC Chen Hung-Jen HJ Chen Hsuan-Yu HY Chang Chi-Sheng CS Hsu Chung-Ping CP Hsia Jiun-Yi JY Chuang Cheng-Yen CY Lin Chin-Hung CH Chen Jeremy J W JJ Chen Kuan-Yu KY Liao Wei-Yu WY Shih Jin-Yuan JY Yu Sung-Liang SL Yu Chong-Jen CJ Yang Pan-Chyr PC Chang Gee-Chen GC
PloS one 20150319 3
<h4>Background</h4>It is important to select appropriate targeted therapies for subgroups of patients with lung adenocarcinoma who have specific gene alterations.<h4>Methods</h4>This prospective study was a multicenter project conducted in Taiwan for assessment of lung adenocarcinoma genetic tests. Five oncogenic drivers, including EGFR, KRAS, BRAF, HER2 and EML4-ALK fusion mutations, were tested. EGFR, KRAS, BRAF and HER2 mutations were assessed by MALDI-TOF MS (Cohort 1). EML4-ALK translocatio ...[more]